1. Home
  2. FORTY vs SRPT Comparison

FORTY vs SRPT Comparison

Compare FORTY & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FORTY

Formula Systems (1985) Ltd.

N/A

Current Price

$125.72

Market Cap

2.1B

Sector

Technology

ML Signal

N/A

Logo Sarepta Therapeutics Inc. (DE)

SRPT

Sarepta Therapeutics Inc. (DE)

N/A

Current Price

$23.21

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FORTY
SRPT
Founded
1985
1980
Country
Israel
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
1998
2000

Fundamental Metrics

Financial Performance
Metric
FORTY
SRPT
Price
$125.72
$23.21
Analyst Decision
Hold
Analyst Count
0
29
Target Price
N/A
$25.85
AVG Volume (30 Days)
412.0
2.8M
Earning Date
05-21-2026
05-06-2026
Dividend Yield
1.32%
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.99
Revenue
N/A
$2,198,237,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$36.65
$7.13
Revenue Growth
N/A
15.58
52 Week Low
$102.01
$14.68
52 Week High
$190.56
$25.32

Technical Indicators

Market Signals
Indicator
FORTY
SRPT
Relative Strength Index (RSI) 64.64 74.39
Support Level $103.12 $15.40
Resistance Level $134.92 $23.71
Average True Range (ATR) 0.45 1.30
MACD 2.53 0.42
Stochastic Oscillator 100.00 99.83

Price Performance

Historical Comparison
FORTY
SRPT

About FORTY Formula Systems (1985) Ltd.

Formula Systems (1985) Ltd is an information technology company that is principally engaged through its directly and indirectly held investees in providing software consulting services, selling and marketing computer-based business solutions and hardware products from a wide range of domestic and international manufacturers, as well as developing proprietary software solutions. It delivers solutions in Israel and in numerous countries to customers with complex IT services needs. It designs and implements IT solutions and software systems that improve the productivity of customers' existing IT assets, enable them to effectively manage their operations and reduce their business risks in the face of changing business environments.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Share on Social Networks: